Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 Combined Chemotherapy for Perioperative Treatment of MHC-II-Negative Gastric/GEJ Adenocarcinoma
NCT07325630Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2025
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Started Nov 2025; status: recruiting.
02
Drugs
IBI363
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07325630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325630.